ICU Sedation
5
Pipeline Programs
4
Companies
2
Clinical Trials
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
3
Early DiscoveryClinical DevelopmentMarket
On Market (1)
Approved therapies currently available
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Maruishi PharmaceuticalJapan - Osaka
1 program1
Dexmedetomidine hydrochloridePhase 31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Orion PharmaDexmedetomidine
Maruishi PharmaceuticalDexmedetomidine hydrochloride
Clinical Trials (2)
Total enrollment: 123 patients across 2 trials
Safety, Tolerability and Efficacy of DEXDOR in Pediatric Patients in ICU
Start: Mar 2017Est. completion: May 201860 patients
Phase 4Completed
Study of DA-9501 In Pediatric Subjects In The Intensive Care Unit
Start: Jul 2016Est. completion: May 201763 patients
Phase 3Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.